Business Context and Reporting Period
Company: Novavax, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 22, 2014
Event: Entry into a Material Definitive Agreement (Amendment to Prime Contract with HHS BARDA).
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The filing focuses exclusively on contract funding terms.
- Base Period Funding Remaining: Access to the remainder of the $97 million base period funding (originally scheduled to end September 23, 2014).
- Additional Option Period Funding: $70 million awarded.
- Total Potential Funding Impact: Extension of access to existing funds plus new option funding totaling $70 million.
Material Changes Versus Prior Period
The filing details a material change to the Company's contract with the Department of Health and Human Services, Biomedical Advanced Research and Development Authority (HHS BARDA):
- Extension: The base period of performance under the Prime Contract has been extended to September 23, 2016.
- Funding Continuity: The Company retains access to the remainder of the $97 million base period funding beyond the original September 23, 2014, deadline.
- New Funding: An additional $70 million in option period funding has been awarded.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on September 23, 2014, announcing the transaction. The remainder of the Prime Contract remains unchanged.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies associated with this amendment. It notes that the description of the Amendment is qualified in its entirety by reference to the full Amendment document, which will be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ended September 30, 2014.
Important Facts for Investor Verification
- Verify the specific milestones or deliverables required to access the $70 million in option period funding.
- Review the full text of the Amendment (Exhibit to the upcoming 10-Q) for any conditions precedent or performance clauses.
- Confirm the impact of the extended performance period (through September 2016) on the Company's cash burn rate and runway.
- Check subsequent filings for the actual drawdown of the remaining $97 million base funding.